Evidence map›Paper›PMID 42204136›Full record

ArticleSignal transduction and targeted therapy2026

Phosphoproteomics distinguishes disease-specific mechanisms for human phospholamban cardiomyopathy reversible by RNA therapy.

Frederik E Deiman, Nils Bömer, Pia Davidsson, Daniela Später, Annet N Linders, Itamar B Dias, Karla F Arevalo Gomez, Antonio Esquivel Gaytan, Jumo Zhu, Anna Walentinsson and 9 more

Abstract read
In one paragraph

Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Frederik E DeimanDepartment of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0001-9793-4683
Nils BömerDepartment of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0001-5926-6960
Pia DavidssonAstraZeneca, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, Gothenburg, Sweden.
Daniela SpäterAstraZeneca, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, Gothenburg, Sweden.
Annet N LindersDepartment of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Itamar B DiasDepartment of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Karla F Arevalo GomezDepartment of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Antonio Esquivel GaytanDepartment of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Jumo ZhuDepartment of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Anna WalentinssonAstraZeneca, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, Gothenburg, Sweden.
Susanna EngbergAstraZeneca, Assays, Profiling & Cell Sciences, Discovery Sciences, BioPharmaceuticals R&D, Gothenburg, Sweden.
Neil HattersleyAstraZeneca, Assays, Profiling & Cell Sciences, Discovery Sciences, BioPharmaceuticals R&D, Gothenburg, Sweden.
Damla EtalAstraZeneca, Translational Genomics, Centre for Genomics Research, BioPharmaceuticals R&D, Gothenburg, Sweden.
Christine AhlstromAstraZeneca, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, Gothenburg, Sweden.
Adam E MullickIonis Pharmaceuticals, Carlsbad, CA, USA.ORCID http://orcid.org/0000-0003-4600-961X
Kenny M HanssonAstraZeneca, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, Gothenburg, Sweden.
Herman H W SilljéDepartment of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Niels Grote BeverborgDepartment of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Peter van der MeerDepartment of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands. p.van.der.meer@umcg.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phospholamban (PLN) p.Arg14del (R14

Indexed as

Calcium-Binding ProteinsCardiomyopathiesCardiomyopathy, DilatedPhosphoproteinsAnimalsHumansInduced Pluripotent Stem CellsMiceMyocytes, CardiacPhospholambanPhosphorylationProteomicsCalcium-Binding ProteinsPhospholambanPhosphoproteins

Identifiers

PMID42204136
PMCPMC13216645

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.